Tapenta
Generic Name
Tapentadol
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| tapenta 75 mg tablet | ৳ 17.00 | ৳ 170.00 |
Description
Overview of the medicine
Tapentadol is an opioid pain medication used to treat moderate to severe acute and chronic pain. It acts through a dual mechanism: as an agonist at the mu-opioid receptor and as a norepinephrine reuptake inhibitor.
Uses & Indications
Dosage
Adults
For moderate to severe acute pain: 50 mg to 100 mg orally every 4-6 hours as needed. For moderate to severe chronic pain: initiate with 50 mg twice daily, adjusted up to a maximum of 250 mg twice daily.
Elderly
No specific dose adjustment for elderly patients based on age alone, but caution and lower initial doses may be appropriate due to potential for decreased renal/hepatic function.
Renal_impairment
Not recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min). In moderate impairment, use with caution and consider dose adjustment.
How to Take
Take orally with or without food. Swallow the tablet whole; do not crush, chew, or break it, especially for extended-release formulations (though 75 mg is usually IR).
Mechanism of Action
Tapentadol has a dual mechanism of action. It acts as an agonist at the mu-opioid receptor, and it inhibits the reuptake of norepinephrine, leading to analgesia by modifying pain signals in the central nervous system.
Pharmacokinetics
Onset
Approximately 30-60 minutes.
Excretion
Excreted almost exclusively via urine (99%), mainly as glucuronide conjugates.
Half life
Approximately 4 hours for tapentadol (active metabolite O-desmethyltapentadol has a half-life of about 11 hours).
Absorption
Rapidly absorbed after oral administration. Absolute bioavailability is about 32%.
Metabolism
Primarily by conjugation (glucuronidation) and some oxidative metabolism by CYP2C9, CYP2C19, and CYP2D6.
Side Effects
Contraindications
- •Significant respiratory depression.
- •Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment.
- •Known or suspected paralytic ileus.
- •Hypersensitivity to tapentadol or any component of the formulation.
- •Concurrent use of monoamine oxidase (MAO) inhibitors or within 14 days of discontinuing MAO inhibitors.
Drug Interactions
MAO Inhibitors
Potentially fatal serotonin syndrome. Contraindicated.
Drugs that Affect CYP2C9, CYP2C19, or CYP2D6
Potential for altered tapentadol or metabolite levels, though tapentadol's metabolism is primarily glucuronidation.
Serotonergic Drugs (e.g., SSRIs, SNRIs, TCAs, triptans)
Increased risk of serotonin syndrome. Monitor for symptoms.
CNS Depressants (e.g., alcohol, benzodiazepines, other opioids)
Increased risk of respiratory depression, profound sedation, coma, and death. Avoid concomitant use or reduce doses of one or both drugs.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and possibly death. Management involves immediate administration of naloxone and supportive care, including maintaining a patent airway and assisted ventilation.
Pregnancy & Lactation
Pregnancy Category C. Not recommended during pregnancy due to potential for fetal harm and neonatal opioid withdrawal syndrome. Excreted in breast milk; therefore, not recommended during lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
2-3 years from manufacturing date
Availability
Pharmacies and hospitals
Approval Status
Approved by regulatory authorities
Patent Status
Generic versions available
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
